These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38444824)

  • 1. Safety and Efficacy of 25 mg/kg and 35 mg/kg vs 10 mg/kg Rifampicin in Pulmonary TB: A Phase IIb Randomized Controlled Trial.
    Perumal Kannabiran B; Palaniappan NA; Manoharan T; Paramasivam PK; Saini JK; Ansari MS; Jayabal L; Aggarwal AN; Garg R; Subramanyam B; Thakur D; Pantula S; P M R; Gs V; Natarajan S; Ammayappan RK; Manpreet B; Ganesan M; Angamuthu D; Chinnaiyan P; Singh M; Chandrasekaran P; Swaminathan S
    Open Forum Infect Dis; 2024 Mar; 11(3):ofae034. PubMed ID: 38444824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Dose Rifampicin Mediated Systemic Alterations of Cytokines, Chemokines, Growth Factors, Microbial Translocation Markers, and Acute-Phase Proteins in Pulmonary Tuberculosis.
    Kathamuthu GR; Bhavani PK; Singh M; Saini JK; Aggarwal A; Ansari MSS; Garg R; Babu S
    Front Pharmacol; 2022; 13():896551. PubMed ID: 35910352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    Boeree MJ; Heinrich N; Aarnoutse R; Diacon AH; Dawson R; Rehal S; Kibiki GS; Churchyard G; Sanne I; Ntinginya NE; Minja LT; Hunt RD; Charalambous S; Hanekom M; Semvua HH; Mpagama SG; Manyama C; Mtafya B; Reither K; Wallis RS; Venter A; Narunsky K; Mekota A; Henne S; Colbers A; van Balen GP; Gillespie SH; Phillips PPJ; Hoelscher M;
    Lancet Infect Dis; 2017 Jan; 17(1):39-49. PubMed ID: 28100438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
    Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD007545. PubMed ID: 23828580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
    Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Moodliar R; Dodd M; Solodovnikova V; Liverko I; Rajaram S; Rassool M; McHugh T; Spigelman M; Moore DA; Ritmeijer K; du Cros P; Fielding K;
    Lancet Respir Med; 2024 Feb; 12(2):117-128. PubMed ID: 37980911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis.
    Jindani A; Borgulya G; de Patiño IW; Gonzales T; de Fernandes RA; Shrestha B; Atwine D; Bonnet M; Burgos M; Dubash F; Patel N; Checkley AM; Harrison TS; Mitchison D;
    Int J Tuberc Lung Dis; 2016 Jun; 20(6):832-8. PubMed ID: 27155189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linezolid for drug-resistant pulmonary tuberculosis.
    Singh B; Cocker D; Ryan H; Sloan DJ
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012836. PubMed ID: 30893466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized, Controlled, Phase III Clinical Trial to Evaluate the Efficacy and Tolerability of Risorine with Conventional Rifampicin in the Treatment of Newly Diagnosed Pulmonary Tuberculosis Patients.
    Patel N; Jagannath K; Vora A; Patel M; Patel A
    J Assoc Physicians India; 2017 Sep; 65(9):48-54. PubMed ID: 29313577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: A randomized controlled trial.
    Laohapojanart N; Ratanajamit C; Kawkitinarong K; Srichana T
    Pulm Pharmacol Ther; 2021 Oct; 70():102056. PubMed ID: 34273498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
    Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
    Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial.
    Lee JY; Kim DK; Lee JK; Yoon HI; Jeong I; Heo E; Park YS; Lee JH; Park SS; Lee SM; Lee CH; Lee J; Choi SM; Park JS; Joh JS; Cho YJ; Lee YJ; Kim SJ; Hwang YR; Kim H; Ki J; Choi H; Han J; Ahn H; Hahn S; Yim JJ
    Trials; 2017 Feb; 18(1):68. PubMed ID: 28193240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
    Wallis RS; Ginindza S; Beattie T; Arjun N; Likoti M; Edward VA; Rassool M; Ahmed K; Fielding K; Ahidjo BA; Vangu MDT; Churchyard G
    Lancet Respir Med; 2021 Aug; 9(8):897-908. PubMed ID: 33740465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of 'Fixed Dose' versus 'Loose' Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled Trial.
    Aseffa A; Chukwu JN; Vahedi M; Aguwa EN; Bedru A; Mebrahtu T; Ezechi OC; Yimer G; Yamuah LK; Medhin G; Connolly C; Rida W; Aderaye G; Zumla AI; Onyebujoh PC;
    PLoS One; 2016; 11(6):e0157434. PubMed ID: 27322164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial.
    Su Q; Liu Y; Zhang G; Xu L; Wang M; Mei S; Garon G; Wu Y; Lv Q; Ma C
    Adv Ther; 2023 Dec; 40(12):5285-5299. PubMed ID: 37770770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of high-dose rifampicin in the management of tuberculosis meningitis: Systematic review and meta-analysis.
    Charlie L; Abay SM; Tesfaye A; Mlera RN; Mwango S; Goretti M
    Int J Mycobacteriol; 2021; 10(3):312-319. PubMed ID: 34494572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement cues of lesion absorption using the adjuvant therapy of traditional Chinese medicine Qinbudan tablet for retreatment pulmonary tuberculosis with standard anti-tuberculosis regimen.
    Zhang SY; Fu JY; Guo XY; Wu DZ; Zhang T; Li C; Qiu L; Shao CR; Xiao HP; Chu NH; Deng QY; Zhang X; Yan XF; Wang ZL; Zhang ZJ; Jiang X; Zheng YJ; Zheng PY; Zhang HY; Lu ZH
    Infect Dis Poverty; 2020 May; 9(1):50. PubMed ID: 32381098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.